SOURCE: ChromoCure, Inc.

August 13, 2009 10:48 ET

ChromoCure, Inc. Releases Second Target Market: Prostate Cancer With Estimated Market Size of $240 Million

RENO, NV--(Marketwire - August 13, 2009) - ChromoCure, Inc. (PINKSHEETS: KKUR) released today the second market estimate in its planned series of business plan disclosures and related market segment analyses. The Company will continue to release public disclosures of its operations, business plans, and target markets. The Company will also release various white papers on its technology subsequent to completion of initial disclosures.

The Company's Disclosure and Discussion of the Prostate Cancer Market can be accessed now at the Company's web site:

http://www.chromocure.com/related-articles/prostate-cancer-market-and-detection-survey/

The disclosure has been properly filed with the OTC Disclosure Service to ensure all investors receive timely public information. Investors can access the Company's public filings at www.pinksheets.com under the Company's "Filings" tab.

The Company is completing its consolidated GAAP financials statements for the year 2007 through 2009. These financials are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines. The Company anticipates filing its consolidated financials on 20 August 2009.

The Company anticipates updating stockholders on the following items:

--  Elimination of significant long-term liabilities and removal from the
    Balance Sheet.
--  Acquisition of intellectual property, technology, and subsequent
    patent filings.
--  Additional appointment to the Company's Advisory and Business
    Development Boards.
--  Acquisition of profitable pathology labs to expand the Company's
    operations.
--  Research and Development agreements with industry partners.
--  Regular updates and commentary on the Company's technology.
--  Industry sector estimates.
    

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.

The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information